Xencor Inc (NASDAQ:XNCR)

15.20
Delayed Data
As of Mar 27
 +0.24 / +1.60%
Today’s Change
7.82
Today|||52-Week Range
19.50
-5.24%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$591.8M

Company Description

Xencor, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company uses proprietary XmAb technology platform to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, asthma, cancer, and other conditions. Xencor was founded Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Contact Information

Xencor, Inc.
111 West Lemon Avenue
Monrovia California 91016
P:(626) 305-5900
Investor Relations:
(626) 737-8013

Employees

Shareholders

Other institutional40.16%
Individual stakeholders33.26%
Mutual fund holders14.69%

Top Executives

Bassil I. DahiyatPresident, Chief Executive Officer & Director
John J. KuchVice President-Finance & Investor Relations
John R. DesjarlaisChief Scientific Officer & Senior VP-Research
Paul A. FosterChief Medical Officer
Lloyd A. RowlandSecretary, Chief Compliance Officer & SVP

To view my watchlist

Not a member yet?

Sign up now for a free account